AQR Capital Management LLC Grows Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• AQR Capital Management LLC significantly increased its holdings in Edwards Lifesciences, acquiring 709,648 shares to reach a total of 918,537 shares, representing a 339.7% increase in their position.
• Several other institutional investors also modified their holdings of Edwards Lifesciences, with 79.46% of the company's stock now owned by institutional investors.
• Edwards Lifesciences reported $1.53 billion in revenue for the last quarter, exceeding estimates, and set a guidance of 0.540-0.60 EPS for Q3 2025.

AQR Capital Management LLC raised its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 339.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 918,537 shares of the medical research company's stock after purchasing an additional 709,648 shares during the quarter. AQR Capital Management LLC owned 0.16% of Edwards Lifesciences worth $65,381,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Advisors Asset Management Inc. lifted its position in shares of Edwards Lifesciences by 2.9% during the 1st quarter. Advisors Asset Management Inc. now owns 16,715 shares of the medical research company's stock valued at $1,212,000 after buying an additional 469 shares in the last quarter. Federation des caisses Desjardins du Quebec increased its stake in Edwards Lifesciences by 6.3% during the first quarter. Federation des caisses Desjardins du Quebec now owns 224,843 shares of the medical research company's stock worth $16,298,000 after acquiring an additional 13,261 shares during the last quarter. Paloma Partners Management Co acquired a new stake in Edwards Lifesciences during the first quarter worth $346,000. Focus Partners Advisor Solutions LLC boosted its stake in Edwards Lifesciences by 76.2% during the first quarter. Focus Partners Advisor Solutions LLC now owns 7,389 shares of the medical research company's stock worth $535,000 after buying an additional 3,195 shares during the period. Finally, Graham Capital Management L.P. acquired a new stake in Edwards Lifesciences in the 1st quarter valued at approximately $1,082,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of EW traded down $0.28 during mid-day trading on Thursday, hitting $78.01. 4,606,741 shares of the company's stock were exchanged, compared to its average volume of 3,505,978. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The business's 50 day moving average is $78.91 and its two-hundred day moving average is $75.35. The firm has a market capitalization of $45.80 billion, a P/E ratio of 11.22, a P/E/G ratio of 3.78 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the business earned $0.70 EPS. The firm's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,014 shares of company stock worth $1,698,844. Company insiders own 1.29% of the company's stock.

Analyst Ratings Changes

EW has been the topic of a number of recent research reports. Wall Street Zen raised Edwards Lifesciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Barclays upped their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Daiwa America raised Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Finally, Morgan Stanley raised their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average price target of $86.45.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.